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Production of α-l-iduronidase in maize for
the potential treatment of a human lysosomal
storage disease
Xu He1, Thomas Haselhorst2, Mark von Itzstein2, Daniel Kolarich3,†, Nicolle H. Packer3,
Tracey M. Gloster4,†, David J. Vocadlo4, Lorne A. Clarke5, Yi Qian6 & Allison R. Kermode1

Lysosomal storage diseases are a class of over 70 rare genetic diseases that are amenable
to enzyme replacement therapy. Towards developing a plant-based enzyme replacement
therapeutic for the lysosomal storage disease mucopolysaccharidosis I, here we expressed
α-l-iduronidase in the endosperm of maize seeds by a previously uncharacterized mRNAtargeting-based mechanism. Immunolocalization, cellular fractionation and in situ RT–PCR
demonstrate that the α-l-iduronidase protein and mRNA are targeted to endoplasmic reticulum
(ER)-derived protein bodies and to protein body–ER regions, respectively, using regulatory
(5′- and 3′-UTR) and signal-peptide coding sequences from the γ-zein gene. The maize
α-l-iduronidase exhibits high activity, contains high-mannose N-glycans and is amenable
to in vitro phosphorylation. This mRNA-based strategy is of widespread importance as plant
N-glycan maturation is controlled and the therapeutic protein is generated in a native form.
For our target enzyme, the N-glycan structures are appropriate for downstream processing,
a prerequisite for its potential as a therapeutic protein.
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ysosomal storage diseases (LSDs) are a broad class of genetic
diseases that are caused by mutations in proteins critical for
lysosomal function; collectively, they represent over 70 dis
orders1–5. In many of these diseases, there is a deficiency of a sin
gle hydrolase enzyme within the lysosome; all are progressive in
nature, as the affected individual is unable to degrade certain macro
molecules, a process essential for normal growth and homeostasis
of tissues.
Many LSDs are amenable to enzyme replacement therapy
(ERT)—a process that takes advantage of plasma membrane receptor
mechanisms that mediate cellular uptake of a recombinant purified
enzyme following its intravenous delivery6. ERT has become estab
lished for six of the LSDs. One of the mucopolysaccharidoses, MPS
I, is an LSD characterized by the deficiency of α-l-iduronidase, an
enzyme involved in the stepwise degradation of glycosaminoglycans;
in severely affected humans, this genetic disease is characterized by
profound skeletal, cardiac, and neurological pathology and death in
early childhood7. The average annual costs of the ERT drug for MPS
I disease (Laronidase or Aldurazyme) range from $300,000 USD
(children) to $800,000 USD (adults). Transgenic plants, cultured
plant cells and seeds are potentially cost-effective and safe systems
for large-scale production of recombinant therapeutic proteins; they
offer considerable advantages as production systems, but are not
without challenges8,9. The majority of human lysosomal enzymes
are glycoproteins and the nature of their N-glycan structures can
influence their stability, transport and biological activity. Within the
Golgi complex of both plant and animal cells, enzymes convert many
of the original high-mannose N-glycans of proteins to complex
N-glycans through sequential reactions that rely on accessibil
ity of the glycan chain(s) to the Golgi-processing machinery9,10.
In the mammalian Golgi complex, many of the N-glycan core
structures (Man3GlcNAc2) are extended further to contain penul
timate galactose and terminal sialic acid residues10. In contrast,
typically processed N-linked glycans of plant proteins are mostly of
a Man3GlcNAc2 structure with or without β-1,2-xylose and/or
α-1,3-fucose9. For glycoprotein therapeutics destined for parenteral
administration (as in ERT), the presence of plant-specific xylose
and/or fucose residues is problematic, because the therapeutic is
potentially highly immunogenic9. Different strategies have been
used to modify the N-glycan processing of plant-made recombinant
proteins; one strategy has been to manipulate subcellular protein
targeting to avoid Golgi transport8,9. This has involved the addition
of C-terminal HDEL/KDEL sequences or similar motifs for endo
plasmic reticulum (ER) retention, or the addition of transmembrane
and cytoplasmic tail sequences that potentially act as anchors for
delivering recombinant proteins to vacuolar compartments inde
pendent of the Golgi complex11. These strategies suffer the draw
backs of requiring the addition of foreign amino acids that remain
on the mature recombinant protein. The HDEL/KDEL strategy is
very efficient for controlling the N-glycosylation of some recom
binant proteins, especially antibodies12–14. However, the efficacy of
this strategy is protein-specific9. For some recombinant proteins,
including human α-l-iduronidase produced in Arabidopsis seeds,
there is clearly an insufficient control of N-glycan maturation15. The
use of vacuolar anchors as a means of controlling complex N-glycan
formation11 is not yet backed up by definitive evidence.
The mechanisms by which proteins of eukaryotic cells are
targeted intracellularly are most commonly mediated through
signals on the protein itself (for example, amino acid or carbohy
drate motifs). More recently, it has been recognized that signals on
mRNAs can also mediate the targeting of proteins to specific intra
cellular regions16,17. γ-Zein storage proteins (prolamins) of maize
seeds are deposited in ER-derived protein bodies and do not transit
through the Golgi complex18. In the present study, we exploited the
potential of maize seeds for hosting the production of recombinant
human α-l-iduronidase by taking advantage of their capacity for


ER–protein body localization of the gene product. We hypothesized
that α-l-iduronidase would be targeted to ER-derived protein bod
ies by mRNA targeting using γ-zein cis-elements. If successful,
the ‘native’ recombinant therapeutic protein (that is, possessing
no foreign amino acid motifs) would stably accumulate in maize
endosperm cells, but have avoided transit through the Golgi
complex and the consequent undesired N-glycan maturation.
We found that the regulatory (5′- and 3′-untranslated region
(UTR)) and signal-peptide-encoding sequences of the γ-zein
gene are sufficient for direct ER–protein body deposition of the
majority of the α-l-iduronidase by an mRNA-targeting-based
mechanism. Moreover, the α-l-iduronidase was enzymatically
active and possessed kinetic characteristics that were comparable
to those of the commercial MPS I ERT product (Aldurazyme).
After immunoadsorbing the minor contaminant of Golgi-modified
enzyme, the affinity-purified maize recombinant α-l-iduronidase
contained exclusively high-mannose N-glycans and was amenable
to in vitro phosphorylation using a recombinant soluble GlcNAc1-phosphotransferase, which is the first step to creating the
mannose-6-phosphate (M6P) lysosomal sorting motif. We discuss
the widespread importance of the targeting of recombinant proteins
to ER-derived protein bodies in maize by mRNA targeting for thera
peutic protein production. Importantly, no topogenic information
from mature-protein-coding sequences of γ-zein was required to
accumulate the human recombinant protein; hence, the production
mechanism avoids the requirement of engineering a proteolytic
cleavage site for removal of non-native amino acids.

Results
Strategy for expression of human α-l-iduronidase in maize. To
investigate the capacity of an mRNA targeting mechanism to direct
the localized accumulation of our recombinant human enzyme in
maize seeds, we designed two constructs—a test construct containing
the putative cis mRNA-targeting elements of the 27-kDa γ-zein gene
and a control construct with substituted sequences (Fig. 1a,b). The
test construct contained the 71-bp 5′-UTR, signal peptide-encoding
sequences and the 3′-UTR terminator, all from the γ-zein gene. As
with the test construct, the control construct contained the γ-zein
promoter and 62 bp of the γ-zein gene 5′-UTR, but in contrast,
contained 10 bp of 5′-UTR and signal peptide-encoding sequences
of the α-l-iduronidase gene; the 3′-region was derived from the Nos
(nopaline synthase) gene.
Northern blot analysis showed that the α-l-iduronidase gene was
transcribed in developing seeds (18–20 days after pollination, DAP)
of independent transgenic lines (Fig. 1c), albeit to variable extents.
Western blot analysis detected α-l-iduronidase protein in mature
or developing T2 seeds of most of the lines (Fig. 1d). The highest
expressing line for the test construct accumulated α-l-iduronidase
in the endosperm at 0.12% total soluble protein (T2 seeds). The
estimated yield of α-l-iduronidase for the highest expressing line
was ~5.2 mg α-l-iduronidase per kg fresh weight (or ~9.4 mg
α-l-iduronidase per kg dry weight) at 20 DAP. The estimated yield
of α-l-iduronidase derived from expression of the control construct
was lower than that derived from the test construct; amongst the
transgenic lines analysed, the maximum was ~0.07% TSP.
-Zein regulatory sequences target mRNA to protein body–ER.
To determine whether γ-zein regulatory sequences are sufficient for
the localization of α-l-iduronidase mRNAs to the protein body–
ER of maize endosperm cells, we examined the distribution of
α-l-iduronidase mRNAs in cryosectioned developing maize
endosperms using in situ RT–PCR. Confocal microscopy showed
that α-l-iduronidase mRNAs of the test lines were co-localized
exclusively to the protein body regions, having a distribution similar
to that of γ-zein mRNAs. In contrast, α-l-iduronidase mRNAs from
the control lines were localized to the protein body and non-protein
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Figure 1 | Constructs and expression of recombinant human -l-iduronidase in transgenic maize. Gene constructs for expression in maize seeds and
the predicted glycosylation status and subcellular localization of the synthesized protein derived from expression of these constructs (a,b). Nos, nopaline
synthase (Nos) gene 3′-region; SP, signal peptide; 3′-UTR, 3′-untranslated region. The human α-l-iduronidase (IDUA) gene was driven by the 1638-bp
γ-zein promoter (constructs shown in a,b). Additional γ-zein gene regulatory sequences flanking the α-l-iduronidase mature coding region included the
71-bp 5′-UTR, the signal peptide-encoding sequences (57 bp) and the 3′-UTR terminator (191 bp; a, Test). The control construct (b) contained in
addition to the 1638-bp γ-zein promoter, 62 bp of the γ-zein gene 5′-UTR, and the 10-bp 5′-UTR and signal peptide-encoding sequences (78 bp) of the
α-l-iduronidase gene. In this case, the 3′-region was from the Nos (nopaline synthase) gene (3′-UTR and transcription termination sequences).
(c) Northern blot to detect human α-l-iduronidase (IDUA) transcripts in the transgenic developing maize endosperms. The ~2.2-kb IDUA transcripts were
detected in different transgenic lines (top panel 1–8); ribosomal RNAs were stained by ethidium bromide to verify the quantity of RNA loaded
(lower panel). UT, untransformed control; 1–7, independent transgenic lines expressing test construct; 8–10, independent transgenic lines expressing
control construct. (d) Western blot analysis to detect α-l-iduronidase in transgenic maize seeds. Proteins were extracted from endosperms of T2
developing seeds expressing the test construct (left panel) and from endosperms of T2 mature seeds expressing the control construct (right panel).
UT, untransformed control; 1–7, indicate independent transgenic lines. Equal protein (50 µg) was loaded in each lane.

body (cisternal ER) regions (Fig. 2). These data suggest that mRNAs of
α-l-iduronidase with 5′-UTR, signal peptide and 3′-UTR sequences
from the γ-zein gene are transported to protein body–ER.
α-l-Iduronidase is targeted to ER-derived protein bodies. To
investigate whether α-l-iduronidase was targeted to protein bod
ies within developing maize endosperm cells, immunolocalization
studies using transmission electron microscopy (TEM) were con
ducted. In the ultrathin sections from the control line, there were
few 10-nm gold particles (labelled α-l-iduronidase) in ER-derived
protein bodies; 10-nm gold particles were predominantly seen in
irregular-shaped organelles (Fig. 3; Supplementary Table S1). The
irregular-shaped organelles were distinguishable from ER-derived
protein bodies and are similar to the legumin-type protein storage
vacuoles19 that may originate from a post Golgi process. However,
in the sections from the test line, 10-nm gold particles were mainly
found in ER-derived protein bodies (Fig. 3; Supplementary Table S1).
γ-Zein protein was preferentially localized at the periphery of pro
tein bodies (labelled by 5-nm gold particles; arrows), consistent
with the reports of others.
Cell fractionation studies further confirmed the localization of
the ‘control’ and ‘test’ α-l-iduronidase (Supplementary Fig. S1).
These data indicate that cis-localization elements in the γ-zein
5′-UTR, signal peptide-encoding and/or 3′-UTR terminator
sequences effectively targeted the α-l-iduronidase RNA molecules
to the protein body–ER in developing maize endosperm cells. Fur
thermore, there was a close relationship between α-l-iduronidase
RNA localization and protein localization in the endomembrane
system of maize endosperm cells.

Recombinant α-l-iduronidase contains high-mannose N-glycans.
α-l-Iduronidase has six consensus signals for N-linked glyco
sylation in the ER; these are all utilized in human cells in which
the enzyme is targeted to the lysosome via the Golgi complex. In
Chinese hamster ovary (CHO) cells hosting production of the
recombinant protein, the enzyme is secreted and all six glycosyla
tion sites are used, but the N-glycans themselves display high intra
site heterogeneity20. Some of the N-glycans of the mature enzyme
remain in a high-mannose form (Asn 372; Asn 415 is mixed high
mannose and complex); at least two of the sites are modified to com
plex forms (Asn 110 and Asn 190); two carry M6P tags (Asn 336
and Asn 451)20. The N-glycan profiles of purified α-l-iduronidase
of transgenic maize seeds were analysed (Fig. 4; Table 1).
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) analysis of
the purified α-l-iduronidase samples, and the specific activities
and yield of recombinant α-l-iduronidase during the purification
procedure are shown in Supplementary Fig. S2 and Supplementary
Table S2. As shown, 91.8% of the N-glycan structures detected
in the ‘test’ α-l-iduronidase were of the oligomannosidic type
(that is, those containing 1–7 hexose residues in addition to the
pentasaccharide N-glycan core) with Man5 being the most abun
dant (41.1%). The remaining 8.2% were complex/hybrid struc
tures, indicating that some of the human α-l-iduronidase likely
transited through the Golgi complex. In contrast, 58.5% of the
N-glycans identified in the ‘control’ α-l-iduronidase belonged to
the complex/hybrid type, carrying xylose, fucose or both sugar
residues attached to the chitobiose core pentasaccharide. These
results further confirm that the ‘test’ α-l-iduronidase is predomi
nantly localized in ER-derived protein bodies and thereby avoids

nature communications | 3:1062 | DOI: 10.1038/ncomms2070 | www.nature.com/naturecommunications

© 2012 Macmillan Publishers Limited. All rights reserved.



ARTICLE

nature communications | DOI: 10.1038/ncomms2070

Rhodamine

in situ RT–PCR

Merged image

γ-Zein

Control

Test

Figure 2 | Subcellular localization of -l-iduronidase mRNAs in developing transgenic endosperm sections. Endosperm sections expressing the
α-l-iduronidase gene (control and test constructs) were subjected to in situ RT–PCR to assess mRNA localization (middle images). ER-derived protein
bodies (1 to 2-µm in diameter) were visualized by staining the sections with rhodamine hexyl ester (left images), a dye that preferentially stains the
prolamin protein bodies of maize. α-l-Iduronidase mRNAs were in situ-labelled by Oregon Green-dUTP (middle images). In the control sections,
α-l-iduronidase mRNAs were seen in both protein body–ER (yellow in the merged image) and in cisternal ER regions (green in the merged image).
In contrast, α-l-iduronidase mRNAs derived from the test construct were seen exclusively in the protein body–ER region. Bar, 10 µm.

N-glycan maturation associated with transit through the Golgi
complex. The small amounts of recombinant α-l-iduronidase con
taining the complex N-glycan sugars xylose and/or fucose in the
‘test’ sample were eliminated by subsequent column chromatogra
phy using an anti-horseradish peroxidase affinity column (Fig. 5).
α-l-Iduronidase has high activity and can be phosphorylated.
Michaelis–Menten kinetics were used to characterize the enzymatic
properties of the maize ‘test’ α-l-iduronidase and the commercial
CHO-cell-derived enzyme product, Aldurazyme (Fig. 6a; Km and
kcat in Supplementary Table S3). CHO-iduronidase has a kcat of
3.9 µmoles min − 1 mg − 1 and a Km of 24 µM; the targeted-maize idu
ronidase has a kcat of 6.4 µmoles min − 1 mg − 1 and a Km of 78 µM.
In addition, the CHO cell-derived α-l-iduronidase and targeted
maize α-l-iduronidase exhibited specific activities of 4.1 and


5.8 µmoles min − 1 mg − 1, respectively, when measured at a substrate
concentration of 1 mM.
Most lysosomal enzymes including α-l-iduronidase require an
M6P tag for efficient uptake/lysosomal delivery in human cells. We
investigated whether the phosphorylation of N-glycan terminal
mannose residues of the ‘test’ α-l-iduronidase could be achieved
in vitro using recombinant soluble UDP–GlcNAc:lysosomal
enzyme N-acetylglucosamine-1-phosphotransferase21 (Fig. 6b).
The efficiency of the phosphotransferase is reliant upon its affin
ity for the target lysosomal hydrolase22; the maize α-l-iduronidase
exhibited a Km (0.87 ± 0.1 µM; Supplementary Table S4), which is
about 25 times less than that of cathepsin D22, suggesting that it
is an effective substrate for the phosphotransferase. The extent of
phosphorylation of a glycoprotein by the phosphotransferase is
influenced by the position of the N-glycans relative to the binding
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site for the phosphotransferase; this modifying enzyme functions
best on target lysosomal hydrolases with Man6–Man8 N-glycans23,
of which the maize α-l-iduronidase has a significant proportion.
Test

The kcat value of the maize α-l-iduronidase (0.52 ± 0.18 min − 1) is
comparable to that of the dephosphorylated CHO cell-produced
α-l-iduronidase (0.32 ± 0.12 min − 1; Supplementary Table S4).
These data show that in vitro phosphorylation is feasible using the
plant-derived mannose-terminated recombinant enzyme.

Control

Discussion
We have used a seed-based system towards developing an alterna
tive to the current mammalian cell-based protein production sys
tems. A unique mRNA targeting strategy was used to control the
plant-specific N-glycosylation of a complex recombinant human
therapeutic enzyme—α-l-iduronidase, a protein possessing six
sites for N-glycosylation. Our approach exploits the natural capacity
of the endosperm storage tissues of maize seeds to stably accumu
late recombinant proteins. The cis mRNA targeting elements pro
vided by sequences of the 27-kDa γ-zein gene successfully mediated
the targeting of α-l-iduronidase transcripts and proteins to protein
body–ER regions and to ER-derived protein bodies, respectively.
Transit of the recombinant protein through the Golgi complex
and the consequent undesirable N-glycan maturation was largely
avoided.
From the point of view of recombinant protein production plat
forms, the current production systems for ERT and the resultant
enzyme therapeutics have some drawbacks that justify an exami
nation of potential alternatives. The prices set for ERT are exceed
ingly high, placing a considerable burden on health-care budgets
and blocking access to ERT in underprivileged countries, and
there is little commercial interest towards developing ERT for the

PB

PSV
PB

PB

Figure 3 | Subcellular localization of human -l-iduronidase protein in
developing maize endosperm cells by transmission electron microscopy.
Transmission electron microscope images of gold-immunolabelled ultrathin sections of maize endosperm. α-l-Iduronidase (IDUA) and γ-zein
were labelled with 10-nm (arrowheads) and 5-nm (arrows) goldconjugated secondary antibodies, respectively. Shown are protein bodies
(PB) in maize endosperm cells expressing the test construct (left) or
control construct (right). PSV = protein storage vacuole. The inset in
the left image shows an enlargement of the two sizes of gold particles.
Bar = 100 nm.
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Figure 4 | N-glycan profiles of maize-derived -l-iduronidase. Summed MS-spectra of N-glycans from ‘control’ α-l-iduronidase (IDUA control: top) and
‘test’ α-l-iduronidase (IDUA test: bottom). In addition to the qualitative N-glycan structure differences, a considerable difference in the signal intensities
between the two samples was detected, indicating different amounts of starting material (see Methods). N-acetylglucosamine (GlcNAc) = blue squares,
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Table 1 | N-glycans identified in maize-derived -l-iduronidase.
Abbreviations
Complex type structures*
Oligomannosidic structures*

MMX
MMF
MMXF
Man5
Man6
Man7
Man8
Man9
Man9 + Hex

Rel. amount (%)
Test

Control

1.5
0.0
6.7
41.1
2.3
8.3
24.1
13.4
2.7

8.8
7.6
42.1
9.4
5.3
10.4
8.2
8.2
0.0

Hex

HexNAc

3
3
3
5
6
7
8
9
10

2
2
2
2
2
2
2
2
2

Fuc

1
1

Xyl
1
1

*N-glycan structures are shown in Fig. 4.

kDa
100
Anti-complex glycan

70

100
Anti-IDUA

70
1

2

Figure 5 | Effects of anti-horseradish peroxidase affinity column on
the presence of α-l-iduronidase containing plant complex N-glycans.
Shows western blot analysis using an antibody specific for plant complex
N-glycans as described in the Supplementary Methods. α-l-Iduronidase
was purified from transgenic maize seeds expressing the test-construct.
Lane 1, 80-ng purified α-l-iduronidase; lane 2, 80 ng α-l-iduronidase
after passing through an anti-horseradish peroxidase affinity column.

ultra-rare LSDs. Safety concerns associated with product contami
nation included the recent and highly publicized viral contami
nation of the CHO cell cultures at Genzyme Corporation, which
resulted in interrupted or dose-reduced treatments, or the initia
tion of alternative treatments24. Perhaps also of importance, there
is considerable N-glycan heterogeneity and variability of glyco
forms of a recombinant protein depending on the CHO cell culture
conditions25 of possible relevance to immunogenicity issues26.
Plant- and seed-based systems provide a potential alternative by
virtue of a minimal possibility of contamination by human patho
gens or prions, and an ability to rapidly increase biomass without the
need for expensive fermentation costs8. Maize as a host for recom
binant protein production has considerable advantages, including
the highest biomass yield among seed crops, ease of transformation/
scale-up and the availability of strong promoters and other generegulatory sequences to facilitate high-level recombinant protein
production. Seeds offer a significant advantage in relation to the
provision of a stable repository of the human recombinant protein8.
In our case, the transgenic maize seeds simply need to be placed
in cool dry conditions after harvest, and the human recombinant
enzyme remains stable. For example, as compared with the specific
activity of the purified protein from freshly harvested mature dry
seeds, that associated with the seeds stored for 14 months at 4 °C
is very similar (5.8 versus 5.1 µmol min − 1 mg − 1, respectively). The
major costs associated with the seed-based production system are
anticipated to be those associated with downstream purification
and processing of the recombinant protein.


The control of glycosylation is paramount to the ultimate utility of
any plant-derived therapeutic; the addition of xylose and/or fucose
sugar residues can elicit immunogenic responses in mammals and
greatly reduce the efficacy of plant-derived recombinant proteins
for pharmaceutical uses9. Our unique strategy may permit the syn
thesis of pharmaceutical and other recombinant proteins containing
predominantly high-mannose N-linked glycans; an affinity column
step removed the small amounts of recombinant enzyme contain
ing xylose and/or fucose. The use of mRNA localization signals as a
strategy for ER retention of plant-synthesized recombinant proteins
is also attractive, as it does not require the fusion of mature proteincoding sequences onto the recombinant therapeutic protein.
Other plant-based platforms have been developed to control
N-glycan maturation. Fusion of the ER retention/retrieval motif
KDEL/HDEL or its extended version (for example, SEKDEL) to
the C terminus of a recombinant protein has been a widely used
strategy to avoid plant-specific N-glycan maturation. In particular,
this strategy has been very effective when applied to the plant-based
production of antibodies. However, KDEL-tagged α-l-iduronidase
produced in Arabidopsis seeds contains predominantly complex and
hybrid N-glycans (88%)15. RNA interference technology has been
employed in plants to silence the expression of the genes encoding
α-1,3-fucosyltransferase and β-1,2-xylosyltransferase. Use of this
strategy for production of a monoclonal antibody generates the pre
dominant N-glycan species GnGn (GlcNAc2Man3GlcNAc2), and
few or no α-1,3-fucose and β-1,2-xylose residues are detectable on
the protein’s N-glycans27,28. Although this strategy addresses prob
lems associated with plant-specific N-glycan maturation in relation
to product immunogenicity, its efficiency in some plant hosts is not
absolute8,9, and further, the predominant N-glycan structures are
such that the approach is not useful for the production of therapeu
tics for LSDs in which mannose-terminated N-glycans or M6P tags
on the recombinant protein are essential for therapeutic delivery/
efficiency. For therapeutic efficacy, the parenterally administered
recombinant enzyme must be competent for endocytosis by human
cells, followed by intracellular targeting to the lysosome. These
receptor-mediated processes are dependent on either the M6P motif
or on mannose-terminated N-glycans on the protein. For those
lysosomal enzymes (such as α-l-iduronidase and several others)
that generally require an M6P tag for efficient targeting/lysosomal
delivery to cells other than macrophages, we show that the highmannose-terminated, plant-derived recombinant enzyme is an
effective substrate for the soluble phosphotransferase as a first step.
The plant-based platform founded on mRNA targeting could
also be used to generate mannosylated therapeutic glycoproteins
that specifically target to the mannose-specific cell surface receptors
of macrophages and dendritic cells. This is relevant for the produc
tion of recombinant glucocerebrosidase for treatment of Gaucher
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Figure 6 | Characterization of maize-derived α-l-iduronidase. (a) Michaelis–Menten plots using the fluorescent substrate 4-methylumbelliferylα-l-iduronide for CHO cell-produced α-l-iduronidase (Aldurazyme) (left panel) and maize-produced α-l-iduronidase (right panel). The data are the
means of three replicate experiments ± s.e. (b) Phosphorylation of maize-produced α-l-iduronidase by the GlcNAc-1-phosphotransferase (α2β2).
The graph is based on data from one typical experiment. Dephosphorylated CHO cell-produced α-l-iduronidase served as a control. The activity of
the GlcNAc-1-phosphotransferase was expressed as pmoles of [3H]GlcNAc-P transferred per h µg − 1 of the GlcNAc-1-phosphotransferase.

disease, in which successful ERT relies primarily on mannose recep
tor-mediated uptake, and it would avoid the three-step downstream
processing that is currently used to expose core mannoses to gener
ate the commercial CHO cell-derived product. A carrot cell-based
system developed by Protalix and Pfizer for production of recom
binant glucocerebrosidase has the advantage of avoiding the need
for this in vitro enzymatic processing, and the product (Taliglu
cerase Alfa) has received recent approval by the US Food and Drug
Administration for treatment of Gaucher disease. However, the
approaches used for production of the carrot glucocerebrosidase
would not be suitable for α-l-iduronidase as an MPS I therapeutic
in relation to N-glycan status, therapeutic efficacy requirements and
potential immunogenicity. Taliglucerase Alfa has extra amino acids
on both the N terminus and the C terminus, and the dominant
N-glycans contain xylose and/or fucose residues29.
Our results provide proof of concept for generating recombinant
proteins with high-mannose N-glycosylation in maize seeds. They
represent an advance in the field of plant-made pharmaceuticals in
relation to generating non-immunogenic recombinant therapeutic
proteins. To develop the platform further for production of M6Ptagged LSD therapeutics, the level of accumulation of the human
recombinant protein needs to be improved (0.12% TSP in the
present study) to advance efficient purification for scale-up. There
are tenable strategies to achieve this, including screening more
independent transgenic lines, applying a combination of selection
and conventional breeding30,31, and subjecting the high-expressing
immature zygotic maize embryos to a dedifferentiation–regenera
tion cycle, which acts to reset the epigenetic status of the transgene32.
Two sequential in vitro enzymatic steps also need to be achieved to
confer the M6P tag on the high-mannose-terminated recombinant
protein. For this, two enzymes are required: the GlcNAc-1-phospho
transferase and the ‘uncovering enzyme’ GlcNAc-1-phosphodiester

α-N-acetylglucosaminidase33, which removes the covering GlcNAc
residue to expose the M6P recognition marker. We have shown
that the high-mannose-terminated α-l-iduronidase is an effective
substrate for the first step using soluble recombinant GlcNAc-1phosphotransferase, and work is in progress to achieve the uncov
ering enzyme step. The therapeutic efficacy of the in vitro proc
essed α-l-iduronidase also needs to be tested in cultured MPS I
(deficient) cells and in the MPS I mouse model.
In relation to our model and other lysosomal enzymes, the plat
form to create the human protein with high-mannose N-glycans
is particularly advantageous, because the product is in a suitable
form (Gaucher disease), or can be subjected to phosphorylation or
to emerging alternative modifications for enhanced biodistribution
of ERT34–36.
Towards a more widespread use of the platform to generate other
types of protein therapeutics (not just LSD therapeutics), down
stream modification to improve the serum half-life of the protein
therapeutic may be required. In the past few years, many efforts have
been geared towards achieving ‘humanized’ complex N-glycan mod
ifications in planta and thus allowing for the elaboration of terminal
galactose or sialic acid residues onto the recombinant glycoprotein
(for example, by transgenic expression of the appropriate mamma
lian enzymes)37–40. A monoclonal antibody (2G12) is sialylated in
Nicotiana benthamiana by transient expression of six mammalian
genes encoding various enzymes of the sialic acid biosynthetic path
way, including a cyclic monophosphate–N-acetylneuraminic acid
synthetase and a CMP–sialic acid transporter39. Likewise, the addi
tion of bisected, triantennary and tetraantennary complex N-glycans
has been achieved by the simultaneous expression of human genes
encoding various N-acetylglucosaminyltransferases (GnTIII, GnTIV
and GnTV) in a glycoengineered N. benthamiana mutant lacking
the machinery for plant-specific complex N-glycosylation (that is,
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the xylosyl and fucosyl transferases)40. Although some of these
modifications may well improve the serum half-life of a protein
therapeutic, notably there are clearly examples where it is advanta
geous for a therapeutic protein to have a shorter in vivo half-life to
avoid cell toxicity or immune responses41–43.
The present platform is flexible in the sense that it generates a
product that is directly amenable to downstream modifications
as appropriate. Downstream-phosphorylated human enzymes
generated by this plant-based strategy may be part of future LSD
therapeutics.

Methods

Constructs for the expression of human -l-iduronidase. To investigate the
potential of targeting the recombinant α-l-iduronidase to protein bodies of maize,
the human α-l-iduronidase (IDUA) gene44 (GenBank accession no. M74715) was
driven by the 1638-bp promoter of the gene encoding 27-kDa γ-zein45 (GenBank
accession no. X53514). Additional regulatory sequences flanking the α-l-iduronidase
mature coding region in control and test constructs are noted in the text describing
Fig. 1a,b. To clone the 5′-UTR, signal peptide-encoding sequences and 3′-UTR
terminator of the γ-zein gene, genomic DNA was extracted from maize Hi-II. For
cloning of the 5′-UTR and signal peptide-encoding sequences, forward primer
5′-CACAGGCATATGACTAGTGGC-3′ and reverse primer 5′-GGAGGT
GGCGCTCGCAGC-3′ were used to PCR-amplify the fragment. For cloning of
the 3′-UTR, the forward primer 5′-ACGCGTCGACAGAAACTATGTGCTG
TAGTA-3′ and reverse primer 5′-CGGAATTCCCTATTAAAAGGTTAAAA
CGT-3′ were used. The DNA sequence encoding the γ-zein signal peptide was
fused in-frame to the mature coding region of the α-l-iduronidase gene. Con
structs were verified by DNA sequencing. Methods for Agrobacterium-mediated
maize transformation are noted in the Supplementary Methods section.
RNA extraction and northern blot analysis. Total RNA was extracted from
developing maize seeds using the Qiagen RNAeasy kit (Qiagen Inc., Mississauga,
ON, Canada). Ten micrograms of total RNA was loaded into each lane and RNA
samples were fractionated on 1.0% agarose formaldehyde gels. Ribosomal RNA
was stained by ethidium bromide to verify the quantity of RNA loaded on the gels
used for northern blots. Following transfer and fixing of RNA to Hybond-XL nylon
membranes (Amersham Life Science, Buckinghamshire, UK), the membranes
were hybridized with a 32P-α-l-iduronidase cDNA probe that had been labelled
using the RTS RadPrime DNA Labelling System (Life Technologies, Gaithersburg,
MD, USA) and [α-32P]-dCTP.
Western blot analysis. Proteins were extracted from endosperms of developing
T2 seeds (20 DAP) or from mature T2 seeds. Fifty micrograms of total soluble
protein was fractionated on 10% SDS–PAGE gels and western blot analysis was
carried out using the Lumigen TMA-6 detection kit as per the manufacturer’s
instructions (GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK)
Anti-α-l-iduronidase46 and anti-γ-zein47 antibodies were used at dilutions of
1:1,000. T2 seeds were produced by either self-pollination or by crossing with the
wild-type maize Hi-II line in cases in which there was male or female sterility.
The yield of α-l-iduronidase was estimated by scanning densitometry of western
blots that had been generated with protein extracts from five seeds (at 20 DAP)
per independent transgenic line. The CHO cell-produced α-l-iduronidase of
known concentration was used as a standard. Some western blot analyses were
conducted on the purified proteins (Supplementary Methods).
In situ RT–PCR. Developing endosperms from test and control lines were excised
from 15 DAP maize seeds. Cryosectioning and fixation were performed as
described by Washida et al.48. In situ RT–PCR was conducted on cryosections
according to Washida et al.48 with modifications. The RT–PCR reaction included
2 mM MgCl2, 0.5 mM MnSO4, 20 µM each of dATP, dCTP and dGTP, 10 µM
dTTP, 10 µM Oregon Green-dUTP (Molecular Probes, Eugene, OR, USA), 5 mM
dithiothreitol, 150 U ml − 1 RNase inhibitor (Fermentas Corp., Ottawa, ON,
Canada), PCR enhancer, 50 U ml − 1 Tth DNA polymerase (Epicentre, Madison,
WI, USA) and 0.5 µM of α-l-iduronidase gene-specific primers: 5′-GGCCAGG
AGATACATCGGTA-3′ and 5′-CTCCCCAGTGAAGAAGTTGG-3′. Primers for
the γ-zein gene were: 5′-TGAGGGTGTTGCTCGTTGCCC-3′ and 5′-CACAT
CGCCGTCAGTTGCTGC-3′. The sections were covered with the above solution
and kept at room temperature for 30 min followed by 60 °C for 30 min. The sec
tions were then subjected to 20–25 amplification cycles (10 cycles for γ-zein) of
94 °C for 1.5 min, 55 °C for 1.5 min, 72 °C for 1.5 min, which was followed by
72 °C for 5 min. After the PCR cycles, the sections were washed and stained with
rhodamine B hexyl ester according to Washida et al.48, mounted in anti-FADE
medium and analysed by confocal microscopy using a Bio-Rad Radiance Plus on
an inverted Zeiss Axiovert with DIC optics (Bio-Rad, Missasauga, ON, Canada).
TEM immunolocalization of -l-iduronidase in maize seeds. Developing endo
sperms (15-17 DAP) were fixed with a high-pressure freezer (Bal-Tec HPM 010


High Pressure Freezer, Zurich, Switzerland). Ultrathin sections were acquired using
a Leica UltracutT UltraMicrotome (Reichert, Austria). The sections were picked
up on 200 mesh nickel grids, and non-specific binding sites were blocked by
immersion in blocking buffer (2% normal goat serum in PBS, pH 7.2) for 1–2 h.
The sections were then labelled with antibody against α-l-iduronidase (1:20
dilution) for 1 h and rinsed extensively followed by incubation with 10 nm goldconjugated goat anti-rabbit IgG (whole molecule; 1:100 dilution) for 1 h. After
rinsing several times, the sections were labelled with the antibody against γ-zein
(1:50) and 5 nm gold-conjugated goat anti-rabbit Fab′ fragments (1:100), sequen
tially. All the antibodies were diluted in 2% goat serum-blocking solution. The
grids were observed under a TEM Model Hitachi-80 (Hitachi, Tokyo, Japan).
Determination of N-glycan profiles of -l-iduronidase. Purified ‘test’
α-l-iduronidase or ‘control’ α-l-iduronidase (~4 µg) was resolved by 10%
SDS–PAGE, and the α-l-iduronidase protein bands were recovered from the gel.
N-glycans were released from tryptic peptides obtained after in-gel digestion
as described by Kolarich and Altmann49, but graphitized carbon liquid chromato
graphy MS/MS (carbon LC-MS/MS) was used for N-glycan analysis50. Therefore,
the released N-glycans were reduced and desalted before analysis as described pre
viously50. An aliquot of the released and reduced glycans was analysed by carbon
LC-MS/MS using an Agilent 1100 capillary LC and an Agilent ion trap for detec
tion using a Thermo Hypercarb column (180 µm ID×100 mm length). N-glycans
were analysed using negative mode according to Wilson et al.50. Oligosaccharide
structures were assigned based on mass, MS/MS spectra and on the knowledge
about plant N-glycosylation51. The relative N-glycan distribution was calculated
from the signal intensities of the monoisotopic m/z signals in the combined MS
spectrum, which was summed over the entire range where the N-glycans are
eluting. If the singly and doubly charged signal was detected, both signals were
taken into account.
The summed MS spectra of N-glycans showed a considerable difference in the
signal intensities between the two samples detected, indicating different amounts
of starting material. Equal amounts of test and control α-l-iduronidase were
loaded onto the gels for fractionation before N-glycan purification, reduction/
desalting and analysis (see above). However, for some unknown reason, some
of the protein from the control α-l-iduronidase sample appeared to have precipi
tated and remained stacked in the wells of the SDS–PAGE gel after electrophoresis.
Small N-glycans consisting of a single GlcNAc residue cannot be released by
enzymatic treatment and can only be detected on the glycopeptides; this was
not investigated in the present study.
Modification of -l-iduronidase by GlcNAc-phosphotransferase. For
in vitro phosphorylation of maize-derived α-l-iduronidase, the recombinant
α2β2 GlcNAc-1-phosphotransferase (0.15 µg) was added to the reaction mixtures
containing various concentrations of maize-derived α-l-iduronidase in 50 mM
Tris-HCl, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 75 µM UDP-[3H]GlcNAc
(1 µCi) and 2 mg ml − 1 bovine serum albumin in a final volume of 50 µl.
Dephosphorylated CHO cell-produced α-l-iduronidase served as a control.
The assay was carried out as described by Qian et al.22. Apparent Km and kcat
values were generated from double-reciprocal plots using a least square
approximation for the best-fit line. The Km and kcat values (Supplementary
Table S4) are the means of three separate determinations. The graph of the activity
of GlcNAc-1-phosphotransferase (α2β2) towards α-l-iduronidase (Fig. 6b) was
based on data from one typical experiment. CHO cell-produced α-l-iduronidase
was dephosphorylated using calf intestinal phosphatase (New England Biolabs Ltd.,
Pickering, ON, Canada) at 0.5 unit µg − 1 Aldurazyme overnight at room tempera
ture. Dephosphorylated CHO cell-produced α-l-iduronidase was dialyzed at 4 °C
overnight in a buffer containing 20 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 150 mM
NaCl and 0.05% Triton X-100.
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